Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Sept. 10, 2024—Pillar Biosciences has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing using rapid next generation sequencing–based liquid biopsy tumor profiling panels for detecting genetic cancer variants.
Sept. 4, 2024—QuidelOrtho has received FDA 510(k) clearance for its Vitros syphilis assay, intended for the qualitative determination of total (IgG and IgM) antibodies to Treponema pallidum-specific antigens in human serum and plasma using the automated Vitros 3600, 5600, and XT 7600 systems.
Sept. 3, 2024—Maine Molecular Quality Controls has launched reference materials for the Cepheid Xpert PML-RARA assay.
Discover the Next-Generation Atlas of Stains from Agilent, a pathology training platform for enhancing your PD-L1 evaluation skills. Explore a repository of real-world cases spanning the full range of PD-L1 expression and unlock a comprehensive suite of PD-L1 evaluation tools. Learn More.
Epredia’s SlideMate Laser provides high-resolution, 600-dpi laser printing on microscope slides. Laser technology, along with specialty slides, create indelible markings that can enhance traceability throughout the life of the slide. Learn More.
Aug. 30, 2024—Qiagen has expanded its master collaboration agreement with AstraZeneca to develop and commercialize companion diagnostics for therapies being developed by AstraZeneca to address chronic diseases.
Aug. 29, 2024—Illumina announced Food and Drug Administration approval of its in vitro diagnostic TruSight Oncology Comprehensive test and its first two companion diagnostic indications.
Aug. 28, 2024—Pillar Biosciences has announced the global launch of OncoReveal Nexus, a research use only next-generation sequencing kit designed to assesses key driver genes for hematological and solid tumor malignancies in one multiplex reaction.
Aug. 26, 2024—Bio-Rad Laboratories has launched its Specialty Immunoassay Plus, a four-level, comprehensive, independent specialty immunoassay quality control designed to monitor the precision of laboratory specialty immunoassay testing procedures.
Aug. 20, 2024—Johnson & Johnson announced Food and Drug Administration approval of Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
